Pierre Krolak-Salmon

Pierre Krolak-Salmon

Auto-generated profile, based on publicly available information

Pierre Krolak-Salmon

Hôpital des Charpennes, institut du vieillissement des hospices civils de Lyon, Villeurbanne

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Neurology
Verified
Journal Article
Open access
PDF file
VPVincent Planche
Vincent Planche
VBVincent Bouteloup
Vincent Bouteloup
IPIsabelle Pellegrin
Isabelle Pellegrin
JMJean-Francois Mangin
Jean-Francois Mangin
BDBruno Dubois
Bruno Dubois
TGthe MEMENTO Study Group
the MEMENTO Study Group
Background and Objective Blood biomarkers for Alzheimer disease (AD) have consistently proven to be associated with CSF or PET biomarkers and effectively discriminate AD from other neurodegenerative diseases. Our aim was to test their utility in clinical practice, from a multicentric unselected prospective cohort where patients presented with a large spectrum of cognitive deficits or complaints. Methods The MEMENTO cohort enrolled 2,323 outpatients with subjective cognitive complaint (SCC) or mild cognitive impairment (MCI) consulting in 26 French memory clinics. Participants had neuropsychological assessments, MRI, and blood sampling at baseline. CSF sampling and amyloid PET were optional. Baseline blood Aβ42/40 ratio, total tau, p181-tau, and neurofilament light chain (NfL) were measured using a Simoa HD-X analyzer. An expert committee validated incident dementia cases during a 5-year follow-up period. Results Overall, 2,277 individuals had at least 1 baseline blood biomarker available (n = 357 for CSF subsample, n = 649 for PET subsample), among whom 257 were diagnosed with clinical AD/mixed dementia during follow-up. All blood biomarkers but total tau were mildly correlated with their equivalence in the CSF (r = 0.33 to 0.46, p < 0.0001) and were associated with amyloid-PET status (p < 0.0001). Blood p181-tau was the best blood biomarker to identify amyloid-PET positivity (area under the curve = 0.74 [95% CI = 0.69; 0.79]). Higher blood and CSF p181-tau and NfL concentrations were associated with accelerated time to AD dementia onset with similar incidence rates, whereas blood Aβ42/40 was less efficient than CSF Aβ42/40. Blood p181-tau alone was the best blood predictor of 5-year AD/mixed dementia risk (c-index = 0.73 [95% CI = 0.69; 0.77]); its accuracy was higher in patients with clinical dementia rating (CDR) = 0 (c-index = 0.83 [95% CI = 0.69; 0.97]) than in patients with CDR = 0.5 (c-index = 0.70 [95% CI = 0.66; 0.74]). A “clinical” reference model (combining demographics and neuropsychological assessment) predicted AD/mixed dementia risk with a c-index = 0.88 [95% CI = 0.86–0.91] and performance increased to 0.90 [95% CI = 0.88; 0.92] when adding blood p181-tau + Aβ42/40. A “research” reference model (clinical model + apolipoprotein E genotype and AD signature on MRI) had a c-index = 0.91 [95% CI = 0.89–0.93] increasing to 0.92 [95% CI = 0.90; 0.93] when adding blood p181-tau + Aβ42/40. Chronic kidney disease and vascular comorbidities did not affect predictive performances. Discussion In a clinic-based cohort of patients with SCC or MCI, blood biomarkers may be good hallmarks of underlying pathology but add little to 5-year dementia risk prediction models including traditional predictors.

1 March 2015 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
ADAline Dorey
Aline Dorey
YTYannick Tholance
Yannick Tholance
AVAlain Vighetto
Alain Vighetto
APArmand Perret-Liaudet
Armand Perret-Liaudet
ILIngolf Lachman
Ingolf Lachman
IQIsabelle QUADRIO
Isabelle QUADRIO
Alzheimer disease (AD) is the most common cause of dementia. In typical AD characterized by progressive memory loss, the diagnosis can be performed with good reliability because of its clinical and neuropsychological profile as well as neuroimaging.1 In atypical AD, including either presentation with focal symptoms unrelated to mesial temporal lobe dysfunction, coexistence of motor signs, or rapid evolution of cognitive decline, the diagnosis is made using AD cerebrospinal fluid (CSF) biomarkers.2-4 However, these atypical AD phenotypes can present with high levels of total tau (T-tau) protein5-8 and/or positive 14-3-3 protein (p14-3-3) in the CSF, reflecting intense neuronal degeneration similar to what is found in Creutzfeldt-Jakob disease (CJD).9-12 Therefore, CSF T-tau and p14-3-3 may not be suitable to provide an in vivo differential diagnosis when the clinical phenotype is atypical. Diagnosing these atypical cases remains challenging and raises suspicion of CJD.13-20 Ideally, an additional biomarker more closely related to the pathological process would be helpful in these cases. This study addresses relevance of determining the total prion protein (t-PrP) level in CSF using a commercially available enzyme-linked immunosorbent assay to discriminate in vivo AD from CJD, especially when AD presents atypically.

25 February 2015 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
PJP. Joussain
P. Joussain
MBM. Bessy
M. Bessy
FFF. Faure
F. Faure
DBD. Bellil
D. Bellil
BLBasile N. Landis
Basile N. Landis
MBMoustafa Bensafi
Moustafa Bensafi

27 September 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
HDHarriet Demnitz-King
Harriet Demnitz-King
JGJulie Gonneaud
Julie Gonneaud
OKOlga M. Klimecki
Olga M. Klimecki
ACAnne Chocat
Anne Chocat
FCFabienne Collette
Fabienne Collette
OGon behalf of the Medit-Ageing Research Group
on behalf of the Medit-Ageing Research Group
Background and Objectives: Self-reflection (the active evaluation of ones thoughts, feelings and behaviours) can confer protection against adverse health outcomes. Its impact on markers sensitive to Alzheimer’s disease (AD), however, is unknown. The primary objective of this cross-sectional study was to examine the association between self-reflection and AD-sensitive markers. Methods: This study utilised baseline data from cognitively unimpaired older adults enrolled in the Age-Well clinical trial and older adults with subjective cognitive decline from the SCD-Well clinical trial. In both cohorts, self-reflection was measured via the reflective pondering subscale of the Rumination Response Scale, global cognition assessed via the Preclinical Alzheimer’s Cognitive Composite 5, and a modified late-life Lifestyle-for-Brain-Health (LIBRA) index computed to assess health and lifestyle factors. In Age-Well, glucose metabolism and amyloid deposition were quantified in AD-sensitive grey matter regions via FDG- and AV45-PET scans, respectively. Associations between self-reflection and AD-sensitive markers (global cognition, glucose metabolism, and amyloid deposition) were assessed via unadjusted and adjusted regressions. Further, we explored whether associations were independent of health and lifestyle factors. To control for multiple comparisons in Age-Well, false discovery rate corrected p-values (pFDR) are reported. Results: A total of 134 (mean age 69.3 ± 3.8 years, 61.9% female) Age-Well and 125 (mean age 72.6 ± 6.9 years, 65.6% female) SCD-Well participants were included. Across unadjusted and adjusted analyses self-reflection was positively associated with global cognition in both cohorts (Age-Well: adjusted-β = 0.22, 95% confidence interval [CI] 0.05-0.40, pFDR = 0.041; SCD-Well: adjusted-β = 0.18, 95% CI 0.03-0.33, p = 0.023) and with glucose metabolism in Age-Well after adjustment for all covariates (adjusted-β = 0.29, 95% CI 0.03-0.55, pFDR = 0.041). Associations remained following additional adjustment for LIBRA but did not survive FDR correction. Self-reflection was not associated with amyloid deposition (adjusted-β = 0.13, 95% CI -0.07-0.34, pFDR = 0.189). Discussion: Self-reflection was associated with better global cognition in two independent cohorts and with higher glucose metabolism after adjustment for covariates. There was weak evidence that relationships were independent from health and lifestyle behaviours. Longitudinal and experimental studies are warranted to elucidate whether self-reflection helps preserve cognition and glucose metabolism, or whether reduced capacity to self-reflect is a harbinger of cognitive decline and glucose hypometabolism. Trial Registration: Age-Well: NCT02977819; SCD-Well: NCT03005652

12 February 2016 in Aging, Neuropsychology, and Cognition
Verified
Journal Article
Closed access
ASAlina-Alexandra Sava
Alina-Alexandra Sava
PKPierre Krolak-Salmon
Pierre Krolak-Salmon
FDFloriane Delphin-Combe
Floriane Delphin-Combe
MCMorgane Cloarec
Morgane Cloarec
HCHanna Chainay
Hanna Chainay
Young individuals better memorize initially seen faces with emotional rather than neutral expressions. Healthy older participants and Alzheimer’s disease (AD) patients show better memory for faces with positive expressions. The socioemotional selectivity theory postulates that this positivity effect in memory reflects a general age-related preference for positive stimuli, subserving emotion regulation. Another explanation might be that older participants use compensatory strategies, often considering happy faces as previously seen. The question about the existence of this effect in tasks not permitting such compensatory strategies is still open. Thus, we compared the performance of healthy participants and AD patients for positive, neutral, and negative faces in such tasks. Healthy older participants and AD patients showed a positivity effect in memory, but there was no difference between emotional and neutral faces in young participants. Our results suggest that the positivity effect in memory is not entirely due to the sense of familiarity for smiling faces.

29 May 2024 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
CHCharlotte Havreng-Théry
Charlotte Havreng-Théry
BOBruno Oquendo
Bruno Oquendo
VZVictoria Zolnowski-Kolp
Victoria Zolnowski-Kolp
PKPierre Krolak-Salmon
Pierre Krolak-Salmon
FBFrançois Bertin-Hugault
François Bertin-Hugault
Joel BelminJoel Belmin
Joel Belmin
Background: A large proportion of nursing home (NH) residents suffer from dementia and effects of conventional anti-dementia drugs on their health is poorly known. We aimed to investigate the associations between exposure to anti-dementia drugs and mortality among NH residents. Methods: This retrospective longitudinal observational study involved 229 French NH and the residents admitted in these facilities since 2014 and having major neurocognitive disorder. From their electronic health records, we obtained their age, sex, level of dependency, Charlson comorbidity index, and Mini mental examination score at admission. Exposure to anti-dementia drugs was determined using their prescription into 4 categories: none, exposure to acetylcholinesterase inhibitors (AChEI) alone, exposure to memantine alone, exposure to AChEI and memantine. Survival until the end of 2019 was studied in the entire cohort by Cox proportional hazards. To alleviate bias related to prescription of anti-dementia drugs, we formed propensity-score matched cohorts for each type of anti-dementia drug exposure, and studied survival by the same method. Results: We studied 25,358 NH residents with major neurocognitive disorder. Their age at admission was 87.1 + 7.1 years and 69.8% of them were women. Exposure to anti-dementia drugs occurred in 2,550 (10.1%) for AChEI alone, in 2,055 (8.1%) for memantine alone, in 460 (0.2%) for AChEI plus memantine, whereas 20,293 (80.0%) had no exposure to anti-dementia drugs. Adjusted hazard ratios for mortality were significantly reduced for these three groups exposed to anti-dementia drugs, as compared to reference group: HR: 0.826, 95%CI 0.769 to 0.888 for AChEI; 0.857, 95%CI 0.795 to 0.923 for memantine; 0.742, 95%CI 0.640 to 0.861 for AChEI plus memantine. Results were consistent in propensity-score matched cohorts. Conclusion: The use of conventional anti-dementia drugs is associated with a lower mortality in nursing home residents with dementia and should be widely used in this population.